Current Fungal Infection Reports最新文献_第10页

Diagnosis of Invasive Aspergillosis in Intensive Care Unit Patients 重症监护病房患者侵袭性曲霉病的诊断

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-05-16 DOI: 10.1007/s12281-020-00383-6

L. Vanderbeke, E. Wijngaerden, J. Maertens, J. Wauters, K. Lagrou

引用次数: 2

Review of the Current Management of Urinary Tract Infections due to Fluconazole-Resistant and Non-Albicans Candida Species 氟康唑耐药和非白色念珠菌引起的尿路感染的当前管理综述

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-05-16 DOI: 10.1007/s12281-020-00388-1

X. Tan, K. Baugh, Z. Bulman, E. Wenzler

引用次数: 3

Antifungal and Oral Anticancer Therapy Drug Interactions 抗真菌和口服抗癌药物相互作用

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-05-07 DOI: 10.1007/s12281-020-00386-3

C. Gustafson, M. Koslosky, J. Leslie, C. Walczak

引用次数: 2

White Piedra, a Rare Superficial Mycosis: an Update 一种罕见的浅表真菌病:最新进展

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-05-06 DOI: 10.1007/s12281-020-00389-0

A. Robles-Tenorio, Kenia Yolanda Lepe-Moreno, J. Mayorga-Rodríguez

引用次数: 6

Updates in the Treatment of Breakthrough Mold Infections 突破性霉菌感染治疗的最新进展

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-04-30 DOI: 10.1007/s12281-020-00387-2

K. Goodlet, K. Spadafora, R. Walia, M. Nailor

引用次数: 1

Invasive Fungal Infections of the Central Nervous System in Immune-Competent Hosts 免疫活性宿主的中枢神经系统侵袭性真菌感染

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-04-11 DOI: 10.1007/s12281-020-00384-5

S. Challa

引用次数: 2

Skin Infections Caused by Emerging Candida Species 新出现的念珠菌引起的皮肤感染

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-03-27 DOI: 10.1007/s12281-020-00380-9

V. M. Espinosa-Hernández, Verónica Morales-Pineda, E. Martínez-Herrera

引用次数: 5

Coccidioidomycosis in Children and Adolescents: an Update 儿童和青少年球虫病的最新进展

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-03-12 DOI: 10.1007/s12281-020-00381-8

M. Maza-Morales, M. Rivas-Calderón, E. Barrón-Calvillo, M. García-Romero

引用次数: 2

Extrapolating Antifungal Animal Data to Humans - Is it reliable? 将抗真菌动物数据推断给人类--可靠吗？

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-03-01 Epub Date: 2020-01-16 DOI: 10.1007/s12281-020-00370-x

Victoria M Stevens, Scott W Mueller, Paul M Reynolds, Robert MacLaren, Tyree H Kiser

{"title":"Extrapolating Antifungal Animal Data to Humans - Is it reliable?","authors":"Victoria M Stevens, Scott W Mueller, Paul M Reynolds, Robert MacLaren, Tyree H Kiser","doi":"10.1007/s12281-020-00370-x","DOIUrl":"10.1007/s12281-020-00370-x","url":null,"abstract":"Purpose of review: This article aimed to review animal models of antifungals and identifies human literature to assess if the extrapolation of results is reliable.Recent findings: Animal studies have helped identify AUC/MIC targets for new drugs and formulations such as isavuconazole and delayed release posaconazole that have translated to successful outcomes in humans. Models have also been influential in the identification of possible combination therapies for the treatment of aspergillosis, such as voriconazole and echinocandins. However, challenges are endured with animal models when it comes to replicating the pharmacokinetics of humans which has been exemplified with the newest itraconazole formulation. Additionally, animal models have displayed a survival benefit with the use of iron chelators and amphotericin for mucormycosis which was not demonstrated in humans.Summary: Animal models have been a staple in the development and optimization of antifungal agents. They afford the ability to investigate uncommon diseases, such as invasive fungal infections, that would otherwise take years and many resources to complete. Although there are many benefits of animal models there are also shortcomings. This is why the reliability of extrapolating data from animal models to humans is often scrutinized.","PeriodicalId":10813,"journal":{"name":"Current Fungal Infection Reports","volume":"14 1","pages":"50-62"},"PeriodicalIF":1.4,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083583/pdf/nihms-1550064.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37762142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet? 将药物基因组学应用于抗真菌选择和给药:我们做到了吗?

IF 1.4

Current Fungal Infection Reports Pub Date : 2020-03-01 Epub Date: 2020-01-16 DOI: 10.1007/s12281-020-00371-w

Matthew A Miller, Yee Ming Lee

{"title":"Applying Pharmacogenomics to Antifungal Selection and Dosing: Are We There Yet?","authors":"Matthew A Miller, Yee Ming Lee","doi":"10.1007/s12281-020-00371-w","DOIUrl":"https://doi.org/10.1007/s12281-020-00371-w","url":null,"abstract":"Purpose of review: This review summarizes recent literature for applying pharmacogenomics to antifungal selection and dosing, providing an approach to implementing antifungal pharmacogenomics in clinical practice.Recent findings: The Clinical Pharmacogenetics Implementation Consortium published guidelines on CYP2C19 and voriconazole, with recommendations to use alternative antifungals or adjust voriconazole dose with close therapeutic drug monitoring (TDM). Recent studies demonstrate an association between CYP2C19 phenotype and voriconazole levels, clinical outcomes, and adverse events. Additionally, CYP2C19-guided preemptive dose adjustment demonstrated benefit in two prospective studies for prophylaxis. Pharmacokinetic-pharmacodynamic modeling studies have generated proposed voriconazole treatment doses based on CYP2C19 phenotypes, with further validation studies needed.Summary: Sufficient evidence is available for implementing CYP2C19-guided voriconazole selection and dosing among select patients at risk for invasive fungal infections. The institution needs appropriate infrastructure for pharmacogenomic testing, integration of results in the clinical decision process, with TDM confirmation of goal trough achievement, to integrate antifungal pharmacogenomics into routine clinical care.","PeriodicalId":10813,"journal":{"name":"Current Fungal Infection Reports","volume":"14 1","pages":"63-75"},"PeriodicalIF":1.4,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12281-020-00371-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37808133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9